William Blair, Udemy
William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform
William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market perform rating in a report released on Monday, Marketbeat Ratings reports. NMRA has been the subject of several other research reports.
We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...
Analysts at William Blair issued their FY2024 EPS estimates for shares of Karman in a report issued on Monday, March 10th.
Fintel on MSN2d
William Blair Upgrades Genmab A (GMAB)Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...
Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...
Fintel on MSN3d
William Blair Upgrades Fastenal (FAST)Fintel reports that on March 10, 2025, William Blair upgraded their outlook for Fastenal (NasdaqGS:FAST) from Market Perform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback